Brief: Sorrento Announces Positive Phase IIa Study Results Of Abivertinib For The Treatment Of Relapsed/Refractory Marginal Zone Lymphoma And Its Plan For A Pivotal Phase III Study
05/07/2023 14:15
July 5 (Reuters) - Sorrento Therapeutics Inc SRNEQ.PK :
* SORRENTO ANNOUNCES POSITIVE PHASE IIA STUDY RESULTS OF
ABIVERTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MARGINAL
ZONE LYMPHOMA (R/R MZL) AND ITS PLAN FOR A PIVOTAL PHASE III
STUDY
Source text for Eikon: ID:nGNX7536W3
Further company coverage: SRNEQ.PK
((reuters.briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20